Careman Pharmaceutical

Careman Pharmaceutical is a clinical-stage biotechnology company headquartered in Guangzhou, China, focused on the discovery and development of innovative small molecule therapeutics for metabolic and autoimmune diseases. The company's lead candidate, KM-501, is a potent and highly selective URAT1 inhibitor currently in Phase 2 clinical trials for the treatment of hyperuricemia and gout. Additionally, Careman is advancing KM-022, a dual TYK2/JAK1 inhibitor designed to treat various autoimmune conditions such as psoriasis and rheumatoid arthritis with improved safety and efficacy. By leveraging its internal medicinal chemistry expertise and drug discovery platform, the company aims to address significant unmet medical needs in the global market. Careman is supported by a strong investor base including SDIC Fund Management and BioTrack Capital.